Table 1.
Analyzed key molecular parameters in the glioblastoma cohort
| Assessed Molecular Alteration | Assessed Number of Patients | Patients | VLSM | ||
|---|---|---|---|---|---|
| Presenting Alteration (1) | Not Presenting Alteration (0) | Proportion (%) Presenting Alteration | Permutation-Adjusted P-value | ||
| MGMT promoter methylation | 221 | 103 | 118 | 46.6 | 0.401 |
| Methylation class1 | |||||
| IDH glioma, subclass high-grade astrocytoma | 237 | 9 | 228 | 3.8 | 0.021 |
| Glioblastoma, IDH wildtype, subclass mesenchymal “mesenchymal” | 237 | 72 | 165 | 30.4 | 0.739 |
| Glioblastoma, IDH wildtype, subclass RTK I “PGFRA” | 237 | 36 | 201 | 15.2 | 0.353 |
| Glioblastoma, IDH wildtype, subclass RTK II “classic” | 237 | 108 | 129 | 45.6 | 0.276 |
| Glioblastoma, IDH wildtype, subclass midline “Midline” | 237 | 5 | 232 | 2.1 | 0.197 |
| Diffuse midline glioma H3 K27M mutant | 237 | 5 | 232 | 2.1 | 0.994 |
| Copy number variation | |||||
| EGFR amplification | 237 | 108 | 129 | 45.6 | 0.325 |
| PDGFRA amplification | 237 | 12 | 225 | 5.1 | 0.762 |
| MDM4 amplification | 236 | 22 | 214 | 9.3 | 0.515 |
| CDK4 amplification | 237 | 174 | 63 | 73.4 | 0.681 |
| PTEN loss | 233 | 186 | 47 | 79.8 | 0.570 |
| TP53 loss | 234 | 19 | 215 | 8.1 | 0.419 |
| CDKN2A loss | 237 | 108 | 129 | 45.6 | 0.747 |
| NF1 loss | 233 | 38 | 195 | 16.3 | 0.722 |
| RB1 loss | 233 | 67 | 166 | 28.8 | 0.148 |
| MYCN amplification | 237 | 5 | 232 | 2.1 | 0.586 |
| TERT gain | 232 | 10 | 222 | 4.3 | 0.289 |
| CDK6 amplification | 237 | 5 | 232 | 2.1 | 0.834 |
| MET amplification | 237 | 7 | 230 | 3.0 | 0.137 |
| CCND2 gain | 230 | 12 | 218 | 5.2 | 0.089 |
| MDM2 amplification | 237 | 14 | 223 | 5.9 | 0.622 |
Abbreviation: RTK, receptor tyrosine kinase.
Annotations: 1 = detailed explanation of methylation classes available via https://www.molecularneuropathology.org/mnp/classifier/1; accessed August 23, 2018.